Ultimo aggiornamento :
19/11/2024
farmaco contro il cancro   Irinotecan  
Iniezione
Stabilità in soluzione Stabilità in miscela Fattori che influenzano la stabilità Compatibilità metodo di iniezione Bibliografia pdf
   Struttura chimica  

Nome commerciale   Nome commerciale     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Asinib Messico
Axinotecan Germania
Campto Africa del Sud, Austria, Belgio, Croazia, Danimarca, Emirati Arabi Uniti, Finlandia, Francia, Giappone, Gran Bretagna, Grecia, India, Iran, Irlanda, Italia, Lussemburgo, Malaysia, Marocco, Norvegia, Paesi Bassi, Polonia, Portogallo, Spagna, Svezia, Svizzera, Tailandia, Tunisia, Turchia, Ungheria
Camptosar Brasile, Canada, Stati Uniti d’America
Irinoliquid Austria
Irnocam Brasile
Bibliografia   Iniezione   Bibliografia : Irinotecan  
tipo pubblicazione
1423 Rivista Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1617 Rivista Li WY, Koda RT.
Stability of irinotecan hydrochloride in aqueous solutions.
Am J Health-Syst Pharm 2002 ; 59: 539-544.
1662 Rivista Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1918 Rivista Dodds HM, Craik DJ, Rivory LP.
Photodegradation of irinotecan (CPT-11) in aqueous solutions : identification of fluorescent products and influence of solution composition.
J Pharm Sci 1997 ; 86, 12: 1410-1416.
1920 Rivista Akimoto K, Kaway A, Ohya K et al.
Photodegradation reactions of CPT-11, a derivative of campothecion, part i: chemical structure of main degradation products in aqueous solution.
Drug Stability 1996 ; 1: 118-122.
1921 Rivista Akimoto K, Kawai A, Ohya K.
Photodegradation reactions of CPT-11, a derivative of campothecion, part ii: photodegradation behaviour of CPT-11 in aqueous solution.
Drug Stability 1996 ; 1; 141-146.
1953 Rivista Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1976 Rivista Trissel LA, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 9, 3: 238-241.
2027 Rivista Walker SE, Shirley L, Puodziunas A.
Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers.
Can J Hosp Pharm 2005 ; 58: 212-222.
2143 Rivista Dodds HM, Robert J, Rivory LP.
The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry.
J Pharm Biomed Anal 1998 ; 17: 785-792.
2168 Rivista Ozdemir FA, Anilanmert B, Pekin M.
Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution.
Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534.
2241 Rivista Thiesen J, Krämer I.
Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags.
J Oncol Pharm Practice 2000 ; 6, 3: 115-121.
2340 Rivista Walker S.E, Law S, Puodziunas A.
Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers
Can J Hosp Pharm 2005 ; 58, 4: 212-222.
2671 Rivista Kaiser J, Thiesen J, Krämer I.
Stability of irinotecan-loaded eluting beads (DC Bead) used for transarterial chemoembolization.
J Oncol Pharm Practice 2010 ; 16: 53-61.
3129 Laboratorio Irinotécan (Campto®) – Résumé des caractéristiques du produits
Pfizer 2008
3369 Laboratorio Levofolinate de sodium Medac - Résumé des caractéristiques du produits
MEDAC France 2011
3670 Rivista Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3873 Rivista Tan X, Hu J.
Incompatibility between irinotecan and fluorouracil injections
Am J Health-Syst Pharm 2016 ; 73:755.

  Mentions Légales